+ Watch BMRN
on My Watchlist
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
THis company is in a good market because Pharmeceuticals will always be needed, but a PE ration of 659 is simply unsustainable. A PE of above 40 is high, but this companies stock is over 600 times more expensive than its earnings per share. That's bad.
Not to mention the fact that if there is *any* bad news or negative press, speculators will abandon ship quickly. With p/e this high, the downside is much greater than the upside. In fact I don't see any upside with the price this high.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions